Systemic inflammation, as measured by the neutrophil/lymphocyte ratio, may have differential prognostic impact before and during treatment with fluorouracil, irinotecan and bevacizumab in metastatic colorectal cancer patients

2014 ◽  
Vol 31 (9) ◽  
Author(s):  
Vincenzo Formica ◽  
Jessica Luccchetti ◽  
David Cunningham ◽  
Elizabeth C. Smyth ◽  
Patrizia Ferroni ◽  
...  
2014 ◽  
Vol 32 (15_suppl) ◽  
pp. e14529-e14529
Author(s):  
Connie Irene Diakos ◽  
Joseph Chan ◽  
Lucy Jankova ◽  
Christopher Toon ◽  
Anthony Gill ◽  
...  

2020 ◽  
Vol 86 (3) ◽  
pp. 220-227
Author(s):  
Zhen Zong ◽  
Tai-Cheng Zhou ◽  
Fu-Xin Tang ◽  
Hua-Kai Tian ◽  
Anan Wang ◽  
...  

We aimed to explore the potential prognostic impact of the metastatic site on the management approach and prognosis of stage IV colorectal cancer patients with synchronous metastases. Synchronous metastatic colorectal cancer patients reported to the Surveillance, Epidemiology, and End Results Program database between 2010 and 2013 were included in this study. Overall survival (OS) was compared between patients with different treatment options using risk-adjusted Cox proportional hazard regression models. Overall, 17,776 patients with stage IV colorectal cancer were identified. Of these patients, 2,052 (11.5%) underwent surgical resection for tumors at both the primary and meta-static sites. Patients who underwent surgical resection of both primary and metastatic sites with liver, lung, and simultaneous liver and lung metastases had a longer median OS ( P < 0.001) than patients who underwent nonsurgical treatments. Cox regression analysis revealed that surgical resection of both primary and metastatic sites was associated with a significantly enhanced OS ( P < 0.001). Colorectal cancer patients with hepatic or pulmonary metastases, who underwent metastasectomy, even in selected patients with both hepatic and pulmonary metastases after multidisciplinary evaluation, could have a better survival benefit than patients who underwent nonsurgical treatments.


2021 ◽  
Vol 22 (15) ◽  
pp. 8002
Author(s):  
Takehito Yamamoto ◽  
Kenji Kawada ◽  
Kazutaka Obama

Colorectal cancer (CRC) is the leading cause of cancer deaths around the world. It is necessary to identify patients with poor prognosis or with high risk for recurrence so that we can selectively perform intensive treatments such as preoperative and/or postoperative chemotherapy and extended surgery. The clinical usefulness of inflammation-related prognostic biomarkers available from routine blood examination has been reported in many types of cancer, e.g., neutrophil–lymphocyte ratio (NLR), lymphocyte–C-reactive protein ratio (LCR), platelet–lymphocyte ratio (PLR), lymphocyte–monocyte ratio (LMR), and so on. Moreover, some scoring systems based on circulating blood cell counts and albumin concentration have been also reported to predict cancer patients’ prognosis, such as the Glasgow prognostic score (GPS), systemic inflammation score (SIS), and prognostic nutritional index (PNI). The optimal biomarker and optimal cutoff value of the markers can be different depending on the cancer type. In this review, we summarize the prognostic impact of each inflammation-related marker in CRC.


Sign in / Sign up

Export Citation Format

Share Document